ESR2 and breast cancer: Nonetheless, in humans avoidance of dietary soy or ingestion of DZN supplements by breast cancer patients receiving estrogen targeted therapy is encouraged (90) despite the fact that the RBA of DZN is 0.003% for ERα and 0.05% for Erβ (91).